Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NA-931 + tirzepatide
- Development stage
- Phase 2
- Lead developer
- Biomed Industries
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Administration
- Oral, Subcutaneous
01
Overview
NA-931 + tirzepatide is a combination therapy currently in phase 2 clinical development for obesity and overweight management. NA-931 is an oral, proprietary quadruple agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors. Tirzepatide is a dual GIP and GLP-1 receptor agonist peptide, FDA-approved for obesity, diabetes, and sleep apnea. The combination aims to provide synergistic effects on weight loss, blood glucose control, and lipid metabolism, leveraging the unique mechanisms of both agents. NA-931 is designed to enhance fat metabolism, preserve muscle mass, and minimize the gastrointestinal and systemic side effects commonly associated with GLP-1 agonists by potentially reducing required tirzepatide doses. Developed by Biomed Industries in collaboration with tirzepatide from Eli Lilly, this regimen addresses multiple targets in obesity pathophysiology.
- Other names
- NA-931NA931NA 931BioglutidetirzepatideZepboundMounjaro
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)IGF-1R (Insulin-like growth factor 1 receptor)GCGR (Glucagon receptor)
Beyond the preview
Go deeper on NA-931 + tirzepatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NA-931 + tirzepatide.